DGAP-News: Newron Receives FDA Rare Pediatric Disease Designation for Sarizotan for the Treatment of Rett Syndrome
Newron Pharmaceut.
WKN: A0LF18 / Name: Newron Pharmaceut. / Aktie / Biotechnologie & medizinische Forschung / Micro Cap /
8,35 €
-6,67 %
DGAP-News: Newron Receives FDA Rare Pediatric Disease Designation for Sarizotan for the Treatment of Rett Syndrome
DGAP-News: Newron Receives FDA Rare Pediatric Disease Designation for Sarizotan for the Treatment of Rett Syndrome
| Unlocking Potential: Discover the transformative power of MetroEHS Pediatric Therapy. Our dedicated team of therapists specializes in ABA, speech, occupational, and feeding therapy, ensuring personalized care for your child's success. Embrace a brighter future with our comprehensive mental health services and convenient teletherapy options.
Neueste Beiträge
williamflores in Nasdaq Market Correction: 2 Brilliant Artificial Intelligence (AI) Stocks to Buy on the Dip, Alphabet Inc. C